Neogen Corporation
Neogen Corporation (NEOG) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
neog · pe ratio · data through May 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Neogen Corporation (NEOG) measures how much investors pay for each dollar of the company's trailing earnings. NEOG's current PE ratio of N/A is calculated by dividing its stock price of $8.90 by its TTM earnings per share of -$2.80.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-05-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%48.6x
MedianQ3 · 75%79.8x
Max
At N/A, NEOG's current P/E is lower than in 0% of its annual fiscal year readings over the past 17 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Neogen CorporationYou NEOG | $1.9B | N/A | — | -$2.80 |
 Azenta, Inc. AZTA | $1.0B | N/A | — | -$1.22 |
 BioLife Solutions, Inc. BLFS | $1.3B | N/A | — | -$0.25 |
 CONMED Corporation CNMD | $1.1B | 26.78x | — | $1.52 |
 Kestra Medical Technologies, Ltd. KMTS | $1.1B | N/A | — | -$2.30 |
 Intellia Therapeutics, Inc. NTLA | $1.5B | N/A | — | -$3.81 |
 NovoCure Limited NVCR | $2.0B | N/A | — | -$1.22 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-05-31Latest FY2025 | — | $-5.03 | — | |
2024-05-31 FY2024 | — | $-0.04 | — | |
2023-05-31 FY2023 | — | $-0.12 | — | |
2022-05-31 FY2022 | 58.98x | $0.45 | -26.1% | |
2021-05-31 FY2021 | 79.80x | $0.57 | +25.7% | |
2020-05-31 FY2020 | 63.48x | $0.57 | +30.7% | |
2019-05-31 FY2019 | 48.58x | $0.58 | -21.7% | |
2018-05-31 FY2018 | 62.02x | $0.61 | +12.3% | |
2017-05-31 FY2017 | 55.22x | $0.43 | +8.8% | |
2016-05-31 FY2016 | 50.74x | $0.36 | -2.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Neogen Corporation (NEOG) measures how much investors pay for each dollar of the company's trailing earnings. NEOG's current PE ratio of N/A is calculated by dividing its stock price of $8.90 by its TTM earnings per share of -$2.80.
Frequently asked questions
NEOG pe ratio · 6 questionsNEOG's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.90 and TTM EPS of -$2.80. Data sourced from Financial Modeling Prep via NEOG's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Neogen Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08